Rituximab occupies an unusual position in our catalogue — it's one of the few products we export with two genuinely distinct buyer profiles, oncology hospitals treating blood cancers and rheumatology clinics treating autoimmune disease, and we handle documentation and dosing-guidance conversations differently depending on which one is placing the order. It works by targeting CD20, a protein found on the surface of B-cells, effectively depleting the population of B-cells responsible for either malignant proliferation (in lymphoma/leukemia) or autoimmune antibody production (in rheumatoid arthritis and related conditions).
- Oncology indications: Non-Hodgkin's lymphoma (multiple subtypes), chronic lymphocytic leukemia
- Autoimmune indications: Rheumatoid arthritis (in combination with methotrexate, for patients who've failed TNF-inhibitor therapy), pemphigus vulgaris, ANCA-associated vasculitis
- Mechanism: Binds CD20 on B-lymphocytes, triggering B-cell depletion through multiple immune-mediated pathways
- Dosing pattern varies significantly by indication: Oncology protocols typically involve weekly or cycle-based dosing over several months; rheumatoid arthritis protocols use a twice-yearly maintenance schedule — a distinction that affects order volume and frequency for distributors serving each buyer type
Rituximab's B-cell-depleting mechanism, while therapeutically valuable, leaves patients meaningfully more vulnerable to infection during and after treatment — which shapes both the pre-treatment screening protocol and the post-infusion monitoring window.
- Contraindications: Severe active infection, significant pre-existing immunosuppression
- Infusion-reaction protocol: Pre-medication (antihistamine, antipyretic, corticosteroid) required before every infusion given documented reaction risk, particularly with the first dose
- Hepatitis B screening: Strongly recommended before first infusion — Rituximab carries a documented risk of reactivating dormant Hepatitis B infection, which can be severe
- Contraception requirement: Required for a minimum of 12 months following the final dose
- Pregnancy/breastfeeding: Not recommended — B-cell depletion can affect the developing immune system
- Certification: WHO-GMP sourced manufacturing partners
- Batch-specific testing: CD20-binding potency validated for every batch before release
- Dual-market awareness: Our team distinguishes between oncology-bound and rheumatology-bound orders at the enquiry stage, since dosing-guidance materials and typical order-volume patterns differ meaningfully between the two buyer types
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| Free Sale Certificate (FSC) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock for export
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global, serving both oncology hospital networks and rheumatology-focused pharmaceutical distributors
- Tracking: Full shipment tracking included as standard
- Institutional buyers: Hospital, distributor, and NGO procurement support across both its oncology and autoimmune-disease use cases
- Unregistered markets: Named-patient supply pathway available
- Rheumatology-specific support: Distributor guidance for rheumatology clinics sourcing Rituximab as a biologic alternative when conventional and TNF-inhibitor therapies haven't controlled disease
What is Rituximab used for?
Treats blood cancers like Non-Hodgkin's lymphoma and CLL, as well as autoimmune conditions like rheumatoid arthritis.
Get Rituximab price from a GMP-compliant Indian supplier — how?
Send strength, destination, and intended use (oncology or autoimmune) for a verified quote.
Does it suppress immunity?
Yes — it depletes B-cells, increasing infection risk, so active infections must be resolved before starting treatment.
Is it safe in pregnancy?
No, it's not recommended during pregnancy or breastfeeding due to its effect on B-cell immunity.
Who supplies Rituximab from India?
WHO-GMP certified manufacturer with full export documentation for both oncology and rheumatology buyers.
